{"id":"ranimustine","rwe":[{"pmid":"40717883","year":"2025","title":"Transplant-Associated Thrombotic Microangiopathy After Autologous Hematopoietic Stem Cell Transplantation Treated With Eculizumab.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"40100513","year":"2025","title":"Discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma in the brain and mantle cell lymphoma in the colon, rectum, and bone marrow.","finding":"","journal":"Brain tumor pathology","studyType":"Clinical Study"},{"pmid":"39085131","year":"2024","title":"Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study.","finding":"","journal":"Journal of clinical and experimental hematopathology : JCEH","studyType":"Clinical Study"},{"pmid":"35599446","year":"2023","title":"Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study.","finding":"","journal":"Asia-Pacific journal of clinical oncology","studyType":"Clinical Study"},{"pmid":"34307847","year":"2021","title":"ICAM1-Negative Intravascular Large B-Cell Lymphoma of the Pituitary Gland: A Case Report and Literature Review.","finding":"","journal":"AACE clinical case reports","studyType":"Clinical Study"}],"tags":[{"label":"ranimustine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AD07","category":"atc"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":66.484,"date":"","count":15,"signal":"Ventricular hypokinesia","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=66)"},{"llr":60.59,"date":"","count":16,"signal":"Haemolytic anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=61)"},{"llr":59.773,"date":"","count":16,"signal":"Thrombotic microangiopathy","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=60)"},{"llr":59.488,"date":"","count":14,"signal":"Hepatitis B","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=59)"}],"commonSideEffects":[{"effect":"Ventricular hypokinesia","drugRate":"LLR 66","severity":"common"},{"effect":"Haemolytic anaemia","drugRate":"LLR 61","severity":"common"},{"effect":"Thrombotic microangiopathy","drugRate":"LLR 60","severity":"common"},{"effect":"Hepatitis B","drugRate":"LLR 59","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cymerin","offLabel":[],"synonyms":["ranimustine","cymerin","cymerine"],"timeline":[],"approvals":[],"brandName":"Cymerin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"ranimustine","explanation":"Imagine your cells are like factories that make copies of themselves. Cymerin gets inside these factories and messes up their ability to make copies, which eventually kills the factories and stops them from making more copies. This can be helpful in treating certain types of cancer.","oneSentence":"Cymerin works by interfering with DNA replication and transcription, ultimately leading to cell death.","technicalDetail":"Cymerin is a nitrogen mustard alkylating agent that cross-links DNA, causing DNA strand breaks and inhibiting DNA replication and transcription."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3519","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=RANIMUSTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RANIMUSTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:30:41.053452","biosimilars":[],"competitors":[{"drugName":"carmustine","drugSlug":"carmustine","fdaApproval":"1977-03-07","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lomustine","drugSlug":"lomustine","fdaApproval":"1976-08-04","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"streptozocin","drugSlug":"streptozocin","fdaApproval":"1982-05-07","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"uracil mustard","drugSlug":"uracil-mustard","fdaApproval":"1962-09-13","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"ranimustine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"carmustine","brandName":"carmustine","genericName":"carmustine","approvalYear":"1977","relationship":"same-class"},{"drugId":"lomustine","brandName":"lomustine","genericName":"lomustine","approvalYear":"1976","relationship":"same-class"},{"drugId":"streptozocin","brandName":"streptozocin","genericName":"streptozocin","approvalYear":"1982","relationship":"same-class"},{"drugId":"uracil-mustard","brandName":"uracil mustard","genericName":"uracil mustard","approvalYear":"1962","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01173887","phase":"PHASE2","title":"Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-07","conditions":["Adult T-cell Leukemia-Lymphoma"],"enrollment":44,"completionDate":"2012-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010958","UNII":"RYH2T97J77","CHEBI":"CHEBI:32089","INN_ID":"5900","UMLSCUI":"C0243666","ChEMBL_ID":"CHEMBL2105348","KEGG_DRUG":"D01760","DRUGBANK_ID":"DB13832","PUBCHEM_CID":"71741","MESH_SUPPLEMENTAL_RECORD_UI":"C020766"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":116,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AD07","allCodes":["L01AD07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jul","pmid":"40717883","title":"Transplant-Associated Thrombotic Microangiopathy After Autologous Hematopoietic Stem Cell Transplantation Treated With Eculizumab.","journal":"Cureus"},{"date":"2025 Apr","pmid":"40100513","title":"Discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma in the brain and mantle cell lymphoma in the colon, rectum, and bone marrow.","journal":"Brain tumor pathology"},{"date":"2024 Sep 28","pmid":"39085131","title":"Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study.","journal":"Journal of clinical and experimental hematopathology : JCEH"},{"date":"2023 Feb","pmid":"35599446","title":"Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study.","journal":"Asia-Pacific journal of clinical oncology"},{"date":"2021 Jul-Aug","pmid":"34307847","title":"ICAM1-Negative Intravascular Large B-Cell Lymphoma of the Pituitary Gland: A Case Report and Literature Review.","journal":"AACE clinical case reports"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cymerin is a small molecule used in the treatment of Adult T-cell Leukemia-Lymphoma. It is administered in combination with VCAP/AMP/VECP(mLSG15) in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}